This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Zoetis (ZTS) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the most recent trading session, Zoetis (ZTS) closed at $152.30, indicating a +0.92% shift from the previous trading day.
Zoetis (ZTS) Stock Moves -1.16%: What You Should Know
by Zacks Equity Research
The latest trading day saw Zoetis (ZTS) settling at $163.11, representing a -1.16% change from its previous close.
United Therapeutics (UTHR) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Zoetis (ZTS) closed the most recent trading day at $163.03, moving -0.08% from the previous trading session.
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Zoetis (ZTS) Dipped More Than Broader Market Today
by Zacks Equity Research
The latest trading day saw Zoetis (ZTS) settling at $160.06, representing a -1% change from its previous close.
Zoetis (ZTS) Laps the Stock Market: Here's Why
by Zacks Equity Research
Zoetis (ZTS) reachead $170.37 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.
Zoetis Stock Down Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
ZTS stock falls despite better-than-expected fourth-quarter results due to a weak 2025 outlook.
Zoetis (ZTS) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zoetis (ZTS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 2.19% and 0.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Zoetis Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in fourth-quarter 2024 in both the United States and International segments.
Curious about Zoetis (ZTS) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zoetis (ZTS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
UTHR or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTHR vs. ZTS: Which Stock Is the Better Value Option?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Zoetis (ZTS) stood at $172.24, denoting a +0.17% change from the preceding trading day.
Zoetis (ZTS) Stock Moves -0.12%: What You Should Know
by Zacks Equity Research
Zoetis (ZTS) closed the most recent trading day at $170.22, moving -0.12% from the previous trading session.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Zoetis (ZTS) closed at $165.02 in the latest trading session, marking a +0.94% move from the prior day.
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Should You Invest in the VanEck Agribusiness ETF (MOO)?
by Zacks Equity Research
Sector ETF report for MOO